Group One Trading’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.56M Sell
198,793
-40,340
-17% -$197K ﹤0.01% 2461
2026
Q1
$835K Buy
239,133
+110,134
+85% +$396K ﹤0.01% 2878
2025
Q4
$441K Buy
128,999
+7,976
+7% +$35.6K ﹤0.01% 3649
2025
Q3
$609K Sell
121,023
-10,067
-8% -$44.4K ﹤0.01% 3496
2025
Q2
$450K Buy
131,090
+50,319
+62% +$125K ﹤0.01% 3529
2025
Q1
$180K Sell
80,771
-8,433
-9% -$24.2K ﹤0.01% 4115
2024
Q4
$261K Buy
89,204
+14,220
+19% +$39.6K ﹤0.01% 3727
2024
Q3
$195K Buy
74,984
+56,009
+295% +$155K ﹤0.01% 3633
2024
Q2
$56.2K Sell
18,975
-13,800
-42% -$52.2K ﹤0.01% 4441
2024
Q1
$148K Buy
32,775
+11,101
+51% +$56.6K ﹤0.01% 3802
2023
Q4
$124K Sell
21,674
-37,450
-63% -$174K ﹤0.01% 4278
2023
Q3
$272K Buy
59,124
+55,913
+1,741% +$340K ﹤0.01% 3535
2023
Q2
$20.7K Sell
3,211
-13,434
-81% -$91.7K ﹤0.01% 5970
2023
Q1
$126K Sell
16,645
-40,444
-71% -$367K ﹤0.01% 4095
2022
Q4
$578K Buy
57,089
+45,777
+405% +$529K ﹤0.01% 2914
2022
Q3
$112K Sell
11,312
-61,976
-85% -$680K ﹤0.01% 4669
2022
Q2
$781K Buy
+73,288
New +$621K ﹤0.01% 2978
2022
Q1
Sell
-84,531
Closed -$800K 7941
2021
Q4
$1.21M Buy
+84,531
New +$1.28M ﹤0.01% 3155
2021
Q3
Sell
-19,222
Closed -$340K 8083
2021
Q2
$423K Buy
+19,222
New +$530K ﹤0.01% 4401

Other funds holding ABCL

Group One Trading's ABCL Position: Q2 2026 in Review

Group One Trading reduced its AbCellera Biologics (ABCL) stake by 17% in Q2 2026, selling an estimated $197K and leaving 198,793 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2461.

Group One Trading first reported a position in ABCL in Q2 2021 and has held it in 19 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Group One Trading held 198,793 shares of AbCellera Biologics worth $1.56M as of Q2 2026.
  • Group One Trading sold 40,340 AbCellera Biologics shares in Q2 2026, an estimated $197K.
  • AbCellera Biologics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #2461 holding.
  • Group One Trading first reported a position in AbCellera Biologics in Q2 2021 and has held it in 19 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.